
Supplements and Featured Publications
- Exploring Novel Second- and Third-Line Approaches in Metastatic Colorectal Cancer
- Volume 1
- Issue 1
Third-Line Treatment Selection in mCRC Is Shaped By Recalibration of Patient Priorities and Molecular Retesting: With Christopher Lieu, MD
Christopher Lieu, MD, expands on current treatment strategies and factors informing third-line sequencing decisions in mCRC.
Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, Christopher Lieu, MD, reviewed current treatment strategies and factors informing sequencing decisions for patients with metastatic colorectal cancer (mCRC) in the third-line setting. Lieu is co-director of the Gastrointestinal Medical Oncology Program, associate director for clinical research, and a professor of medicine in the Department of Medical Oncology at the University of Colorado Cancer Center in Aurora.
In our exclusive interview, Dr Lieu explained how treatment priorities are recalibrated to account for changing goals of care when a patient with mCRC reaches the third-line setting; emphasized the importance of molecular retesting in this setting to identify new actionable mutations; and discussed how efforts to shift effective therapies earlier in the treatment course could reduce the need for third-line options in the future.
_____
That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air.
*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.
Articles in this issue
Related to this article








